Reprint
Novel Aspects of Lipoprotein Metabolism with Focus on Systemic Inflammation
Edited by
March 2020
248 pages
- ISBN978-3-03928-214-2 (Paperback)
- ISBN978-3-03928-215-9 (PDF)
This is a Reprint of the Special Issue Novel Aspects of Lipoprotein Metabolism with Focus on Systemic Inflammation that was published in
Medicine & Pharmacology
Public Health & Healthcare
Summary
With cardiometabolic diseases still topping the list of mortality causes and in facing the obesity and diabetes epidemic, there remains a great need to better understand the pathophysiological derangements underlying these conditions. During the past years, it has become increasingly appreciated that low grade systemic inflammation is a common hallmark of cardiometabolic disorders—not only concerning diabetes and atherosclerotic cardiovascular disease but also involving non-alcoholic fatty liver disease. Recently developed high-throughput laboratory techniques for lipidomics and metabolomics have enabled researchers to discern novel crosstalk pathways between lipid phenotypes and enhanced chronic inflammation. With this Special Issue of the Journal of Clinical Medicine, entitled “Novel Aspects of Lipoprotein Metabolism with a Focus on Systemic Inflammation”, researchers were invited to submit original papers and reviews on various topics, in particular, at the interface of lipid metabolism and inflammation.
Format
- Paperback
License and Copyright
© 2020 by the authors; CC BY-NC-ND license
Keywords
carbamoylation; chronic kidney disease; lipoproteins; infrared spectroscopy; Breast cancer; cholesterol; 27-hydroxycholesterol; HDL; LDL; cholesterol-lowering therapies; biomarker; anti-apolipoprotein A-1 antibodies; renal transplant recipient; HDL function; prognosis; cholesterol; acute coronary syndrome; biomarkers; anti-apolipoprotein A-I autoantibodies; GRACE score; C-statistics; adipose tissue; ANGPTL3; ANGPTL4; ANGPTL8; lipid metabolism; cholesterol efflux capacity; coronary artery calcium score; obesity; anti-apoA-1 IgG; autoantibodies; cardiovascular disease; C-reactive protein; HDL; paraoxonase-1; cardiovascular disease; myocardial infarction; diabetic cardiomyopathy; cytokines; interleukin 1β; inflammation; CANTOS; canakinumab; retinol binding protein 4; retinol; lipoprotein subfractions; large VLDL; small LDL; Type 2 diabetes mellitus; metabolic syndrome; nuclear magnetic resonance spectroscopy; betaine; trimethylamine N-oxide related metabolites; nuclear magnetic resonance spectroscopy; type 2 diabetes mellitus; anti-apolipoprotein A-1 IgG; familial hypercholesterolemia; cholesterol homeostasis; foam cells; miR-33a; TLR2/4; passive diffusion; microvesicles; inflammation; lipoproteins; LDL cholesterol; microparticles; cardiovascular disease; platelets; endothelial cells; leukocytes; atherothrombosis; HDL; lipids; inflammation; atherosclerotic cardiovascular disease (ASCVD); cardiovascular events; GlycA; non-alcoholic fatty liver; sodium intake; insulin resistance; fatty liver index; hepatic steatosis index; HOMA-IR; gut microbiota; lipoprotein metabolism; metabolic disorder; adiponectin; free thiols; nuclear magnetic resonance spectroscopy; phospholipid transfer protein activity; triglycerides; type 2 diabetes mellitus; large very low density lipoproteins; ANGPTL8; visceral adipose tissue (VAT); obesity; endothelial cells